Formally established by the institution in 2006 to address the growing demand for bioinformatics expertise at Mayo Clinic, the Bioinformatics Core Shared Resource (BIC) is a new shared resource of the Cancer Center. The mission of the Shared Resource is to assist Mayo Clinic Cancer Center (MCCC) investigators in leveraging intramural and extramural sources of biological information to promote discoveries that will impact patient care. To this end, the BIC offers a suite of services to support investigators with the manipulation, preprocessing, and interpretation of genomics, microarray, and proteomics data. These services include: sequence analysis and comparative genomics;gene and SNP selection for association studies;data parsing and formatting;gene ID conversion, biological pathway and networks analysis;data preprocessing;including quality control;and management and education regarding public and local databases and bioinformatics applications. BIC has assembled a team of 13 computer scientists and 12 bioinformatics experts who work collaboratively with biostatisticians to provide analytical support to investigators at all three Mayo campuses. NCI related goals for bioinformatics is assured by dedicated Shared Resource support for the evaluation and integration of caBIG projects into Mayo's infrastructure. BIC provides critical 'value-add'to MCCC investigators in providing (i) investigator support during planning and execution of high throughput experiments;(ii) development of bioinformatics tools and education programs;and (iii) infrastructure for experimental techniques and analytical methods validation, including quality control workflows for genotyping data, preprocessing workflows for gene expression profiles, validation of copy number variation, and high throughput sequencing;and platforms for data integration and mining. Over the past year, BIC has supported 36 MCCC investigators, accounting for more than 50% of the Shared Resource's total usage, and offered 22 classes and training programs attended by more than 40 MCCC investigators and personnel.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-38
Application #
8382243
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
38
Fiscal Year
2012
Total Cost
$228,642
Indirect Cost
$69,531
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Paulus, A; Akhtar, S; Yousaf, H et al. (2017) Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J 7:e565
Li, Mulin Jun; Li, Miaoxin; Liu, Zipeng et al. (2017) cepip: context-dependent epigenomic weighting for prioritization of regulatory variants and disease-associated genes. Genome Biol 18:52
Finnes, Heidi D; Chaffee, Kari G; Call, Timothy G et al. (2017) Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. Leuk Lymphoma 58:1376-1383
Patnaik, Mrinal M; Barraco, Daniela; Lasho, Terra L et al. (2017) Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 92:542-548
Pathangey, Latha B; McCurry, Dustin B; Gendler, Sandra J et al. (2017) Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens. Oncotarget 8:10785-10808
Russell, Stephen J; Peng, Kah-Whye (2017) Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther 25:1107-1116
Ertz-Archambault, Natalie; Kosiorek, Heidi; Taylor, Gretchen E et al. (2017) Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia. JAMA Oncol 3:936-943
Peacock, Justin G; Harmsen, William S; Link, Michael J et al. (2017) Risk of Delayed Lymph Node Metastasis in Clinically N0 Esthesioneuroblastoma. J Neurol Surg B Skull Base 78:68-74
Miyoshi, Jinsei; Toden, Shusuke; Yoshida, Kazuhiro et al. (2017) MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep 7:43393
Wu, Y; Vadgama, J V (2017) Androgen Receptor as a Potential Target for Treatment of Breast Cancer. Int J Cancer Res Mol Mech 3:

Showing the most recent 10 out of 1086 publications